

31 March 2008

The Manager Companies
Australian Stock Exchange Limited
20 Bridge Street
Sydney NSW 2000

(8 pages by email)

Dear Madam

RE: NEW ISSUE ANNOUNCEMENT AND APPLICATION FOR QUOTATION

In accordance with Listing Rule 2.8.2, I attach an Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities which have been issued pursuant to the approval by members at the General Meeting of Members held on 28 March 2008. In summary, the following shares have been issued pursuant to this shareholder approval:

- 60,000,000 fully paid ordinary shares for the acquisition of the medical devices business of TUTA Healthcare Pty Limited.
- 20,000,000 fully paid ordinary shares for \$1.0 million cash.

In addition, I advise that the Company's 10,000,000 Terminating Preference Shares ('Performance Shares') have, in accordance with their conversion conditions, converted to 102 fully paid ordinary shares.

Yours sincerely

Peter J. Nightingale Company Secretary

pjn4322

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of	entity	
		BMDI International Limited
ABN		
	30 096 048 912	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully paid ordinary shares

Number of *securities issued or to be issued (if known) or maximum number which may be issued

80,000,102 fully paid ordinary shares

3 Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares ranking pari passu with existing ordinary shares

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

Yes

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

60,000,000 shares for the acquisition of the medical devices business of TUTA Healthcare Pty Limited.
20,000,000 for \$1.0 million cash.
102 for the conversion of 10,000,000 Terminating Preference Shares to fully paid ordinary shares.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) For shares for the acquisition of the medical devices business of TUTA Healthcare Pty Limited and to provide funds for the continued development and promotion of the Company's new and existing product ranges, meet professional costs associated with the acquisition of the TUTA business and for working capital purposes.

Also for the conversion of the Company's Terminating Preference Shares to fully paid ordinary shares in accordance with the conversion conditions.

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

31 March 2008

8 Number and *class of all *securities quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
181,764,366	Fully paid ordinary shares

⁺ See chapter 19 for defined terms.

Number +Class 9 31 August 2008 Number and +class of all 1,500,000 +securities not quoted on ASX **\$0.06** options (including the securities in clause 31 August 2009 1,500,000 2 if applicable) **\$0.10 options** 10 Dividend policy (in the case of a trust, distribution policy) on the Remains unchanged increased capital (interests)

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers	
	(or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32	of the	do *security holders dispose ir entitlements (except by sale th a broker)?	N/A
33	+Desp	atch date	N/A
		Quotation of secur	
34	Type (tick o	of securities one)	
(a)	✓	Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
		at have ticked box 34(a	
Tick to docume		e you are providing the informat	ion or
35		_ ·	securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36			y securities, a distribution schedule of the additional ber of holders in the categories
37		A copy of any trust deed for the	ne additional *securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which ⁺ quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
		<u>-</u>	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	N/A	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (<i>including</i> the securities in clause 38)	N/A	N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that noone has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

a. 1	D (21	3. / 1	2000
Sign here:	Date: 31	March	- 71 H 1X
DIZH HULU.	 Daic. Di	wiaich	$\angle (\mathcal{M})$

Company Secretary
Print name: Peter J. Nightingale

== == == == ==